文献速递流行病学与生物统计临床试验与 GCP

covid-19疫苗接种后心肌炎和心包炎的发病率、危险因素、自然史及假设机制:活体证据合成与综述

Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
PubMed 文献 · BMJ · 2022-07-13

该活体证据合成与综述检索了Medline、Embase和Cochrane Library(2020年10月6日至2022年1月10日),纳入46项研究,评估covid-19 mRNA疫苗接种后心肌炎和心包炎的发病率、危险因素、临床表现、短期与长期结局及假设机制。结果显示,男性青少年和年轻成年人心肌炎发病率最高,使用BNT162b2相比mRNA-1273及延长给药间隔可能降低风险,心肌炎临床病程似乎良性但长期随访数据有限。

要点

  • 男性青少年和年轻成年人是mRNA疫苗接种后心肌炎最高风险人群。
  • 12-17岁男性心肌炎发病率范围为每百万50-139例(低确定性)。
  • 18-29岁人群mRNA-1273接种后心肌炎发病率可能高于Pfizer疫苗(中等确定性)。

核心结论

  • 男性青少年和年轻成年人是mRNA疫苗接种后心肌炎最高风险人群。
  • 对该人群,使用Pfizer疫苗而非Moderna疫苗及等待超过30天接种第二剂可能更可取。
  • 5-11岁儿童心肌炎发病率非常罕见但确定性低。
  • mRNA相关心肌炎的临床病程似乎良性,但长期随访数据有限。

研究设计与样本

  • 活体证据合成与综述,检索Medline、Embase和Cochrane Library从2020年10月6日至2022年1月10日,以及参考文献列表和灰色文献至2021年1月13日。
  • 纳入46项研究:14项关于发病率,7项关于危险因素,11项关于特征和短期病程,3项关于长期结局,21项关于机制。
  • 纳入标准为大型(>10000名参与者)或基于人群或多站点观察性研究和监测数据(发病率和危险因素)、病例系列(n≥5)、观点、信件、综述和原始研究(机制)。
  • 使用改良Joanna Briggs Institute工具评估偏倚风险,使用GRADE评定发病率和危险因素的证据确定性。

主要发现

  • 12-17岁男性心肌炎发病率为每百万50-139例(低确定性);18-29岁男性为每百万28-147例(中等确定性)。
  • 5-11岁女孩和男孩及18-29岁女性接种BNT162b2后心肌炎发病率可能少于每百万20例(低确定性)。
  • 18-29岁人群接种mRNA-1273后心肌炎发病率可能高于Pfizer疫苗(中等确定性)。
  • 12-17、18-29或18-39岁人群第二剂mRNA疫苗间隔≥31天相比≤30天,心肌炎或心包炎发病率可能更低(低确定性)。
  • 青少年和成人中,大多数(>90%)心肌炎病例为男性,中位年龄20-30岁,症状在第二剂后2-4天出现(71-100%),大多数住院(≥84%)持续时间短(2-4天)。

关键数值与推荐

  • 12-17岁男性心肌炎发病率每百万50-139例(低确定性)。
  • 18-29岁男性心肌炎发病率每百万28-147例(中等确定性)。
  • 5-11岁女孩和男孩及18-29岁女性接种BNT162b2后心肌炎发病率可能少于每百万20例(低确定性)。
  • 18-29岁人群接种mRNA-1273相比Pfizer疫苗,心肌炎发病率可能更高(中等确定性)。
  • 12-17、18-29或18-39岁人群第二剂间隔≥31天相比≤30天,心肌炎或心包炎发病率可能更低(低确定性)。

临床怎么用

  • 作者认为,对该人群(青少年和年轻成年男性),使用Pfizer疫苗而非Moderna疫苗及等待超过30天接种第二剂可能更可取。

局限性

  • 5-11岁儿童的临床病程和短期结局仅有一项小型病例系列(n=8)。
  • 心包炎数据有限,患者年龄、性别、发病时间和住院率比心肌炎有更多变异。
  • 长期随访数据有限。
  • 临床危险因素数据非常有限。
  • 16种假设机制的直接支持或反驳证据很少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To synthesise evidence on incidence rates and risk factors for myocarditis and pericarditis after use of mRNA vaccination against covid-19, clinical presentation, short term and longer term outcomes of cases, and proposed mechanisms. DESIGN: Living evidence syntheses and review. DATA SOURCES: Medline, Embase, and the Cochrane Library were searched from 6 October 2020 to 10 January 2022; reference lists and grey literature (to 13 January 2021). One reviewer completed screening and another verified 50% of exclusions, using a machine learning program to prioritise records. A second reviewer verified all exclusions at full text, extracted data, and (for incidence and risk factors) risk of bias assessments using modified Joanna Briggs Institute tools. Team consensus determined certainty of evidence ratings for incidence and risk factors using GRADE (Grading of Recommendations, Assessment, Development and Evaluation). ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Large (>10 000 participants) or population based or multisite observational studies and surveillance data (incidence and risk factors) reporting on confirmed myocarditis or pericarditis after covid-19 mRNA vaccination; case series (n≥5, presentation, short term clinical course and longer term outcomes); opinions, letters, reviews, and primary studies focused on describing or supporting hypothesised mechanisms. RESULTS: 46 studies were included (14 on incidence, seven on risk factors, 11 on characteristics and short term course, three on longer term outcomes, and 21 on mechanisms). Incidence of myocarditis after mRNA vaccines was highest in male adolescents and male young adults (age 12-17 years, range 50-139 cases per million (low certainty); 18-29 years, 28-147 per million (moderate certainty)). For girls and boys aged 5-11 years and women aged 18-29 years, incidence of myocarditis after vaccination with BNT162b2 (Pfizer/BioNTech) could be fewer than 20 cases per million (low certainty). Incidence after a third dose of an mRNA vaccine had very low certainty evidence. For individuals of 18-29 years, incidence of myocarditis is probably higher after vaccination with mRNA-1273 (Moderna) compared with Pfizer (moderate certainty). Among individuals aged 12-17, 18-29, or 18-39 years, incidence of myocarditis or pericarditis after dose two of an mRNA vaccine for covid-19 might be lower when administered ≥31 days compared with ≤30 days after dose one (low certainty). Data specific to men aged 18-29 years indicated that the dosing interval might need to increase to ≥56 days to substantially drop myocarditis or pericarditis incidence. For clinical course and short term outcomes, only one small case series (n=8) was found for 5-11 year olds. In adolescents and adults, most (>90%) myocarditis cases involved men of a median 20-30 years of age and with symptom onset two to four days after a second dose (71-100%). Most people were admitted to hospital (≥84%) for a short duration (two to four days). For pericarditis, data were limited but more variation than myocarditis has been reported in patient age, sex, onset timing, and rate of admission to hospital. Three case series with longer term (3 months; n=38) follow-up suggested persistent echocardiogram abnormalities, as well as ongoing symptoms or a need for drug treatments or restriction from activities in >50% of patients. Sixteen hypothesised mechanisms were described, with little direct supporting or refuting evidence. CONCLUSIONS: These findings indicate that adolescent and young adult men are at the highest risk of myocarditis after mRNA vaccination. Use of a Pfizer vaccine over a Moderna vaccine and waiting for more than 30 days between doses might be preferred for this population. Incidence of myocarditis in children aged 5-11 years is very rare but certainty was low. Data for clinical risk factors were very limited. A clinical course of mRNA related myocarditis appeared to be benign, although longer term follow-up data were limited. Prospective studies with appropriate testing (eg, biopsy and tissue morphology) will enhance understanding of mechanism.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Pillay J, Gaudet L, Wingert A, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022. PMID: 35830976. doi:10.1136/bmj-2021-069445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。